SBFM — Sunshine Biopharma Balance Sheet
0.000.00%
- $6.57m
- -$2.72m
- $34.87m
Annual balance sheet for Sunshine Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.99 | 2.05 | 21.8 | 16.3 | 9.69 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.002 | 0.008 | 1.91 | 2.55 | 3.87 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1.03 | 2.2 | 27.3 | 24.9 | 26 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.02 | 0.007 | 1.15 | 1.01 | 1.48 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 1.05 | 2.2 | 29.2 | 27.3 | 30.6 |
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 1.05 | 0.091 | 6.93 | 5.55 | 6.31 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2 | 1.99 | 7.62 | 6.14 | 7.06 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0.955 | 0.212 | 21.6 | 21.2 | 23.5 |
| Total Liabilities & Shareholders' Equity | 1.05 | 2.2 | 29.2 | 27.3 | 30.6 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |